A Hatch-Waxman case in Delaware stemming from AMTA Labs’ proposed generic version of Upsher-Smith’s Qudexy XR (topiramate) extended-release capsules has closed with a swift settlement.
AMTA Labs has swiftly forged a patent-litigation settlement agreement in the US on undisclosed terms for Upsher-Smith’s Qudexy XR (topiramate) extended-release capsules – several years after Glenmark debuted generic competition to the branded migraine headache prophylaxis and treatment for certain seizures.
The Hong Kong firm had been sued by Upsher-Smith only in January this year for alleged infringement of its US...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
